Literature DB >> 33560468

Temporal trends and outcome of splenectomy in adults with immune thrombocytopenia in the USA.

Antoine Finianos1, Hata Mujadzic2, Heather Peluso3, Tarik Mujadzic4, Ali Taher1, Marwan S Abougergi5,6.   

Abstract

Splenectomy is one of the treatments of immune thrombocytopenia (ITP) with a high response rate. However, it is an irreversible procedure that can be associated with morbidity in this setting. Our aim was to study the trends of splenectomy in adults with ITP, and the factors associated with splenectomy and resource utilization during these hospitalizations. We used the National (Nationwide) Inpatient Sample (NIS) to identify hospitalizations for adult patients with a principal diagnosis of ITP between 2007 and 2017. The primary outcome was the splenectomy trend. Secondary outcomes were (1) incidence of ITP trend, (2) in-hospital mortality, length of stay, and total hospitalization costs after splenectomy trend, and (3) independent predictors of splenectomy, length of stay, and total hospitalization costs. A total of 36,141 hospitalizations for ITP were included in the study. The splenectomy rate declined over time (16% in 2007 to 8% in 2017, trend p < 0.01) and so did the in-hospital mortality after splenectomy. Of the independent predictors of splenectomy, the strongest was elective admissions (adjusted odds ratio [aOR]: 22.1, 95% confidence interval [CI]:17.8-27.3, P < 0.01), while recent hospitalization year, older age, and Black (compared to Caucasian) race were associated with lower odds of splenectomy. Splenectomy tends to occur during elective admissions in urban medical centers for patients with private insurance. Despite a stable ITP hospitalization rate over the past decade and despite listing splenectomy as a second-line option for management of ITP in major guidelines, splenectomy rates consistently declined over time.

Entities:  

Keywords:  Immune thrombocytopenia; In-hospital mortality; Inpatient utilization; National inpatient sample; Splenectomy

Year:  2021        PMID: 33560468     DOI: 10.1007/s00277-021-04449-4

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  2 in total

1.  Length of stay, hospitalization cost, and in-hospital mortality in US adult inpatients with immune thrombocytopenic purpura, 2006-2012.

Authors:  Ruopeng An; Peizhong Peter Wang
Journal:  Vasc Health Risk Manag       Date:  2017-01-20

2.  Idiopathic thrombocytopenic purpura.

Authors:  L Kayal; S Jayachandran; Khushboo Singh
Journal:  Contemp Clin Dent       Date:  2014-07
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.